registHER: A prospective, longitudinal cohort study of women with HER2 positive metastatic breast cancer.

被引：0

作者：

Tanchiu, E

Kaufman, PA

Paik, S

Ulcickas-Yood, M

Mayer, M

Tripathy, D

Rugo, H

Brufsky, A

机构：

[1] Canc Res Network, Plantation, FL USA

[2] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA

[3] NSABP, Pittsburgh, PA USA

[4] Episource LLC, Hamden, CT USA

[5] Patient Advocate, New York, NY USA

[6] Univ Texas, SW Med Ctr, Dallas, TX 75230 USA

[7] Univ Calif San Francisco, San Francisco, CA 94143 USA

[8] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：46S / 46S

页数：1

共 50 条

[41] Prospective Evaluation of Serum HER2 and HER2 Expression on Circulating Tumor Cells in Patients with Metastatic Breast Cancer within the DETECT Study
Mueller, V
Riethdorf, S.
Rack, B.
Janni, W.
Fasching, P.
Pantel, K.
Gebauser, G.
Solomayer, E.
Aktas, B.
Kasemier-Bauer, S.
Fehm, T.
[J]. CANCER RESEARCH, 2009, 69 (24) : 662S - 662S
[42] Frequency of dose reductions of abemaciclib in metastatic and early-stage hormone positive, HER2 negative breast cancer.
Ter-Zakarian, Anna
Donovan, Lauren N.
Nasraty, Farah
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[43] Extended survival in women receiving trastuzumab for brain metastases from HER2 positive metastatic breast cancer
不详
[J]. EJC SUPPLEMENTS, 2006, 4 (02): : 163 - 163
[44] Pyrotinib in the treatment of women with advanced HER2 positive breast cancer: A multicenter, prospective, real-world study.
Feng, Jifeng
Zhang, Lili
Wu, Xiaohong
Zhou, Jun
Zhu, Mingzhen
Zhang, Yusong
Yu, Hao
Han, Zhengxiang
Guo, Yujiang
Guan, Xiaoqing
Wang, Xufen
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[45] The effects of HER2 monoclonal antibody in women with HER2-overexpressing metastatic breast cancer
Boer R.
[J]. Breast Cancer Research, 1 (1)
[46] Phase I study of LZM005, a HER2 antibody, as monotherapy or in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.
Xue, Cong
Yao, Herui
Lin, Ying
An, Xin
Chen, Meiting
Dong, Yugang
Li, Su
Shi, Yanxia
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[47] Treatment Patterns and Clinical Outcomes in Elderly Patients with HER2-Positive Metastatic Breast Cancer from the registHER Observational Study.
Kaufman, P. A.
Brufsky, A. M.
Mayer, M.
Rugo, H. S.
Tripathy, D.
Ulcickas, Yood M.
Feng, S.
Wang, L. I.
Brammer, M. G.
Yardley, D. A.
[J]. CANCER RESEARCH, 2011, 71
[48] Prospective longitudinal multi-omics study of palbociclib resistance in hormone receptor+/HER2-metastatic breast cancer.
Park, Yeon Hee
Im, Seock-Ah
Park, Kyunghee
Wen, Ji
Min, Ahrum
Bonato, Vinicius
Park, Seri
Ram, Sripad
Lee, Dae-Won
Kim, Ji-Yeon
Lee, Kyung-Hun
Lee, Won-Chul
Lee, Jisook
Kim, Hyunseon
Lee, Won-Woo
Choi, Yoon-La
Weinrich, Scott
Ryu, Han Suk
Park, Woong-Yang
Kan, Zhengyan
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[49] Correlation between HER2 amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2 positive breast cancer.
Antolin, Silvia
Garcia-Caballero, Lucia
Reboredo, Cristina
Molina Diaz, Aurea
Mosquera, Joaquin
Vazquez-Boquete, Angel
Gallego, Rosalia
Paz Santiago, Maria
Concha, Angel
Eva Perez, Maria
Calvo, Lourdes
Garcia-Caballero, Tomas
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[50] Efficacy of HER2 inhibitors in metastatic breast cancer by discordance in HER2 amplification status between primary and metastatic breast cancer
Van Raemdonck, E.
Berteloot, P.
Laenen, A.
Han, S.
Van Nieuwenhuysen, E.
Salihi, R.
Concin, N.
Vergote, I.
Floris, G.
Wildiers, H.
Punie, K.
Neven, P.
[J]. CANCER RESEARCH, 2019, 79 (04)

← 1 2 3 4 5 →